Encouraging results have been achieved by co-blocking LAG-3 and PD-1; for example, recent reports from the RELATIVITY-047 Phase III clinical trial indicated that the median progression-free survival time of the group with melanoma treated using relatlimab and nivolumab was 10.1 months, while that of the group receiving therapy targeting PD-1 alone was 4.6 months (39). Here, LAG3 is linked to melanoma.